Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.11.2012 | consensus report | Ausgabe 21-22/2012

Wiener klinische Wochenschrift 21-22/2012

Clinical application of interventional renal sympathetic denervation: recommendations of the Austrian Society of Hypertension 2012

Wiener klinische Wochenschrift > Ausgabe 21-22/2012
Priv.-Doz. Dr. Thomas Weber, Univ.-Prof. Dr. Robert Zweiker, Univ.-Prof. Dr. Bruno Watschinger, Dr. Peter Grüner, PhD Dr. Christian Koppelstätter, Dr. Mathias C. Brandt, Univ.-Prof. Dr. Jörg Horina, Asst. Prof. Dr. Helmut Brussee, Dr. Katharina Hohenstein, Dr. Thomas Lambert, Univ.-Doz. Dr. Johann Auer, Univ.-Prof. Dr. Uta C. Hoppe


Increased activity of the sympathetic nervous system plays a major role in the pathophysiology of primary arterial hypertension. Interventional renal sympathetic denervation (RSD) is a novel percutaneous treatment, decreasing sympathetic activity and consecutively blood pressure by ablating sympathetic nervous fibers located in the adventitia of the renal arteries. The procedure has been tested in several clinical trials in patients with resistant hypertension (defined as systolic office blood pressure > 160 mmHg—in diabetic patients > 150 mmHg—treated with ³ 3 antihypertensive drugs) and caused a meaningful blood pressure reduction, lasting for at least 3 years. So far, no major adverse events have been identified; however, data on the long-term consequences are lacking. The present position paper of the Austrian Society of Hypertension is aiming to assist in choosing possible indications for RSD in clinical routine, based on the available evidence in 2012.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 21-22/2012

Wiener klinische Wochenschrift 21-22/2012 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in Wien

Mitteilungen November 2012

MUW resarcher of the month

Researcher of the Month